Aurobindo Pharma on Wednesday, June 3, inaugurated TheraNym, a dedicated biologics contract manufacturing organisation (CMO), marking its entry into the biologics contract manufacturing segment.
The company added that TheraNym has been positioned as one of India's largest dedicated biologics contract manufacturing facilities, with MSD (known as Merck & Co. in the US and Canada) joining as its anchor customer.Satakarni Makkapati, CEO, Biologics and Director, Aurobindo Pharma Limited, said, “TheraNym represents a defining moment in large-scale biologics manufacturing in India and a proud milestone for Aurobindo Pharma.
Designed and built to the highest international standards, the facility is positioned to serve the supply chains of leading global pharmaceutical companies.
TheraNym adds meaningful capacity and capability to the MSD supply chain, helping enable compliant,and reliable supply of products to the patients who need them most," said Dave Maraldo, MSD Executive Vice President and President, MSD Manufacturing Division.
Shares of Aurobindo Pharma ended 0.41% higher at ₹1,435 on the NSE on June 3.Also Read: Rooftop solar leads India's clean energy hiring boom: Study
Aurobindo Pharma on Wednesday, June 3, inaugurated TheraNym, a dedicated biologics contract manufacturing organisation (CMO), marking its entry into the biologics contract manufacturing segment.
As per a press release filled at NSE, company said that facility, located in Borapatla near Hyderabad, was inaugurated by Telangana Minister for IT, Industries & Commerce and Legislative Affairs D. Sridhar Babu and Telangana Minister for Science and Technology Damodar Raja Narasimha.
The company added that TheraNym has been positioned as one of India's largest dedicated biologics contract manufacturing facilities, with MSD (known as Merck & Co. in the US and Canada) joining as its anchor customer.Satakarni Makkapati, CEO, Biologics and Director, Aurobindo Pharma Limited, said, “TheraNym represents a defining moment in large-scale biologics manufacturing in India and a proud milestone for Aurobindo Pharma. Designed and built to the highest international standards, the facility is positioned to serve the supply chains of leading global pharmaceutical companies."He added that as the global biologics market continues its remarkable expansion, TheraNym stands ready to help bring biologic therapies to patients worldwide, reliably and more affordably than before.The company said the project represents its strategic expansion into biologics manufacturing, a segment witnessing growing global demand.Also Read: Indiabulls to raise ₹1,000 crore via preferential issue of convertible warrants “This innovative partnership reflects a shared commitment to strengthening global access to critical biologic medicines. TheraNym adds meaningful capacity and capability to the MSD supply chain, helping enable compliant,and reliable supply of products to the patients who need them most," said Dave Maraldo, MSD Executive Vice President and President, MSD Manufacturing Division.
The facility is equipped with 15 KL bioreactors, downstream processing suites, aseptic fill-finish capabilities and quality control laboratories. It has been designed in line with international regulatory expectations.
Shares of Aurobindo Pharma ended 0.41% higher at ₹1,435 on the NSE on June 3.Also Read: Rooftop solar leads India's clean energy hiring boom: Study
